How has been the historical performance of Astrazeneca Phar?

Answer:The historical performance of Astrazeneca Phar shows significant growth in net sales and operating profit over the years, with a notable increase in 2025.

Breakdown:
Astrazeneca Phar has demonstrated a strong upward trend in net sales, rising from 728.29 Cr in March 2019 to 1,716.29 Cr in March 2025. This growth is reflected in the total operating income, which also increased from 728.29 Cr to 1,716.29 Cr over the same period. The company's total expenditure, excluding depreciation, rose from 657.00 Cr in March 2019 to 1,462.32 Cr in March 2025, indicating a significant investment in operations. Operating profit (PBDIT) has similarly improved, climbing from 87.58 Cr in March 2019 to 294.60 Cr in March 2025. However, profit before tax peaked in March 2024 at 219.54 Cr before dropping to 156.36 Cr in March 2025, while profit after tax also decreased from 161.51 Cr in March 2024 to 115.74 Cr in March 2025. The company's total assets increased from 691.72 Cr in March 2020 to 1,476.56 Cr in March 2025, with total liabilities rising correspondingly from 691.72 Cr to 1,476.56 Cr. Cash flow from operating activities improved significantly to 65.00 Cr in March 2025, up from 27.00 Cr in March 2024, contributing to a closing cash and cash equivalent of 536.00 Cr in March 2025. Overall, Astrazeneca Phar has shown robust growth in sales and assets, although profit margins have fluctuated in recent years.